Evaluation of Effect of Doxycycline Verses Placebo on Retinal Function and Diabetic Retinopathy

Phase 2

Completed

Conditions: Diabetic Retinopathy

Interventions: Drug: doxycycline monohydrate
Drug: Placebo

Registration Number: NCT00917553

Lead Sponsor: Thomas Gardner

Brief Summary: This 24 month randomized research study will evaluate whether doxycycline can slow the deterioration or improve retinal function among patients with mild to moderate non-proliferative diabetic retinopathy.

Detailed Description: The objective of this proof-of-concept study is to investigate whether doxycycline can slow the deterioration or improve retinal function among patients with mild to moderate NPDR (with abnormal retinal function defined as a foveal sensitivity \< 30.91 dB on Matrix frequency doubling perimetry \[FDP\]). Based on results of the END DR Study, the primary visual function endpoint in the POC 2 Study will be performance on the Matrix Frequency Doubling Technology Perimeter. This test was the most sensitive to NPDR of the visual function endpoints the investigators evaluated in the END DR Study. This selection is aggressive because the investigators lack natural history data to estimate the 2-year rate of change in the endpoint; in fact, a major output of this POC 2 Study will be 2-year natural history data using several visual function endpoints. The investigators are enrolling patients who have moderate dysfunction; that is, patients who fall outside the 95% confidence interval of normal performance on FDP. These patients will have the opportunity to improve their FDP performance to "normal" levels as well as progress to more severe FDP impairment associated with more advanced disease. Secondary endpoints include visual acuity, contrast sensitivity, visual field, and dark adaptation. The tests will be performed in the Ophthalmology Department of the Penn State College of Medicine. The 24-month proof-of-concept clinical study will involve a prospective, randomized, double-masked clinical trial including 60 adult patients with type 1 or type 2 diabetes who have mild to moderate NPDR (ETDRS levels 20 to 43), and in whom retinal photocoagulation is not anticipated (by the investigator) within the subsequent 2 years. Participants will be randomized to receive either doxycycline monohydrate 50mg or an identical placebo once daily for 24 months.

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 33

Inclusion Criteria

age ≥ 18 years old
diagnosis of type 1 or type 2 diabetes mellitus (defined as current regular use of oral anti-hyperglycemia agents and/or insulin for the treatment of diabetes)
have a hemoglobin A1c < 11% at pre-qualification visit
able and willing to give informed consent
best-corrected ETDRS visual acuity (10) in study eye ≥ 69 letters (20/40)
mild to moderate non-proliferative diabetic retinopathy (ETDRS levels 20 to 43) (11), and in whom retinal photocoagulation is not anticipated (by the investigator) within the subsequent 2 years
able to perform reliable visual field and dark adaptation testing
central subfield thickness on OCT ≤ 275 microns
media clarity and pupil dilation sufficient for high-quality fundus photographs
abnormal retinal function defined as:
abnormal FDP function as defined by a foveal sensitivity ≤ 30.91 dB

Exclusion Criteria

prior panretinal photocoagulation in the study eye
prior focal/grid laser photocoagulation in the macula in the study eye
intraocular pressure in the study eye > 22 mmHg by Goldmann tonometry
history of pars plana vitrectomy in the study eye
systemic or intravitreal anti-VEGF agent to the study eye or the fellow eye within the past 3 months
peribulbar steroid injection to the study eye or the fellow eye within the past 6 months
intravitreal triamcinolone acetonide to the study eye within the past 4 months
expectation by the investigator that retinal photocoagulation or other treatment for diabetic retinopathy (e.g., focal/grid laser to study eye, intravitreal triamcinolone acetonide to study eye, intravitreal anti-VEGF agent to study or fellow eye, ruboxistaurin or systemic anti-VEGF agent for diabetic macular edema) will be administered in the subsequent 24months
an ocular condition (other than diabetes) is present in the study eye that, in the opinion of the investigator, might alter visual acuity during the course of the study (e.g., retinal vein occlusion, uveitis or other ocular inflammatory disease, neovascular glaucoma, Irvine-Gass Syndrome, etc)
anticipated need for cataract surgery in the study eye in the subsequent 24 months in the opinion of the investigator
history of major ocular surgery (including cataract surgery, scleral buckle, any intraocular surgery, etc) in the study eye within prior 6 months or anticipated within the subsequent 24 months following randomization
aphakia in the study eye
history of YAG capsulotomy performed in the study eye within 2 months prior to randomization

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
doxycycline monohydrate	doxycycline monohydrate	-
Placebo	Placebo	Placebo

Primary Outcome Measures

Name	Time	Method
The Mean Change in the Foveal Sensitivity of Matrix Frequency Doubling Perimetry (FDP) From Baseline in the Treated Group Compared to the Placebo Group	Baseline and 24 months

Secondary Outcome Measures

Name	Time	Method
Change Thickness Thickness	Baseline and 24 months	Anatomic outcomes were assessed through optical coherence. Positive numbers indicate increases in thickness.
Change in Macular Volume	Baseline and 24 months
Number of Participants With Progression to PDR, and Single or Multiple Step Progression in ETDRS Diabetic Retinopathy Severity Level	Baseline to 24 months	Participants are shown categorically by whether they reached PDR, or whether their diabetic retinopathy levels changed by one grade or more, as analyzed by fundus photography.
Number of Participants Who Developed Vitreous or Preretinal Hemorrhage	24 months	Any participants who developed vitreous or preretinal hemorrhage were counted. Had there been any preretinal hemorrhages (a subcategory of vitreous hemorrhage) these would have been shown as a separate row.